CARCINOMA METAPLÁSICO DE MAMA EM PACIENTE JOVEM: UM RELATO DE CASO

2018 ◽  
Vol 5 (2) ◽  
pp. 41-46
Author(s):  
Matheus Fávero Damasceno ◽  
Alice Assumpção Soares ◽  
Carolina Silva Delgado ◽  
Patricia Fraga Paiva ◽  
Emilio Pereira Assis
Keyword(s):  
Breast Cancer ◽  
Breast Carcinoma ◽  
Literature Review ◽  
Aggressive Behavior ◽  
Biological Behavior ◽  
Cáncer De Mama ◽  
Carcinoma Breast ◽  
Breast Neoplasia ◽  
The World ◽  
Metaplastic Breast Carcinoma

RESUMO CONTEXTUALIZAÇÃO: O câncer de mama é a 2ª neoplasia mais comum entre as mulheres no Brasil e no mundo. Essa doença, relativamente rara antes dos 35 anos possui características altamente heterogêneas, patologia específica e comportamento biológico distinto. Dentre os Subtipos, o Carcinoma Mamário Metaplásico possui uma incidência de apenas 0,2-5% nos casos de câncer de mama. O objetivo desse estudo é relatar, a partir de uma comparação e revisão de literatura, o caso de uma paciente portadora do carcinoma mamário metaplásico, abaixo de 40 anos, pela raridade do tipo histológico e de seu comportamento agressivo. DESCRIÇÃO DA EXPERIÊNCIA: A paciente inicialmente aos 28 anos apresentou o Papiloma Atípico e 2 anos depois desenvolveu o Carcinoma Mamário Metaplásioco, além de múltiplos nódulos metastáticos pulmonares, comum desse subtipo, e hepáticos. CONSIDERAÇÕES FINAIS: Deve-se destacar que é difícil extrair conclusões definitivas quanto ao prognóstico e tratamento destas lesões, uma vez que elas são muito infrequentes na maior parte de série de casos publicados.   Palavras-chave: Carcinoma Mamário Metaplásico, Carcinoma Mamário, Neoplasia Mamária Malígna, Câncer de Mama. ABSTRACT CONTEXT: The breast cancer is the 2nd most common neoplasia among women in Brasil and around the world. This disease, relatively rare before the age of 35 years, has highly heterogeneous characteristics, especific pathology and distinct biological behavior. Among the subtypes, the Metaplastic Breast Carcinoma has an incidence of only 0,2-5% between the breast cancer cases. The purpose of this study is to report, from a comparison and literature review, the case of a patient with Metaplastic Breast Carcinoma, below 40 yers old, due to the rarity of the histological type and its aggressive behavior. EXPERIENCE DESCRIPTION: The patient, inicially 28 years old presented the Atipic Papilloma and 2 years later developed the Metaplastic Breast Carcinoma, in adittion to multiple metastatic pulmonary nodes, common of the type, and hepatic. FINAL CONSIDERATIONS: It should be noted that it is difficult to draw definitive conclusions about the prognosis and treatment of these lesions, since they are very infrequent in most of the series of published cases. Keywords: Metaplastic Breast Carcinoma, Breast Carcinoma, Malign Breast Neoplasia, Breast Cancer.

scholarly journals Oral Metastasis of Metaplastic Breast Carcinoma in a Patient with Neurofibromatosis 1

2014 ◽  
Vol 2014 ◽  
pp. 1-7 ◽  
Author(s):  
Ana Paula Molina Vivas ◽  
Luana Eschholz Bomfin ◽  
Clovis Antonio Lopes Pinto ◽  
Ulisses Ribaldo Nicolau ◽  
Fabio Abreu Alves
Keyword(s):  
Breast Cancer ◽  
Breast Carcinoma ◽  
English Literature ◽  
Neurofibromatosis Type ◽  
Nerve Sheath Tumors ◽  
Peripheral Nerve Sheath Tumors ◽  
Increased Risk ◽  
Multiple Metastases ◽  
Metaplastic Breast Carcinoma ◽  
Oral Metastasis

Neurofibromatosis type 1 (NF1) has been associated with an increased risk for development of malignancy, especially malignant peripheral nerve sheath tumors. In addition, recently, literature has demonstrated an increased risk of breast cancer in women with NF1. The present paper shows a 53-year-old woman with NF1 who presented with metaplastic breast carcinoma and developed multiple metastases, including mandible. Furthermore, we reviewed the English literature, found 63 cases showing the association between NF1 and breast cancer, and added one more case. The present study demonstrated an important association between NF1 and breast cancer. Until the present time, there has been only one case of metaplastic breast carcinoma associated with NF1. Curiously, in our case the oral metastasis corresponded to sarcomatous component of metaplastic breast carcinoma.

Survival in metaplastic breast carcinoma: A case series

2021 ◽  
Vol 41 (1) ◽  
pp. 133-136
Author(s):  
Rafael Everton Assunção Ribeiro da Costa ◽  
Danilo Rafael da Silva Fontinele ◽  
Paula Catarina Dalia Rego Medeiros ◽  
Sabas Carlos Vieira
Keyword(s):  
Breast Cancer ◽  
Breast Carcinoma ◽  
Case Series ◽  
Nodal Metastasis ◽  
Breast Cancer Patients ◽  
Rare Type ◽  
Aggressive Clinical Course ◽  
Metaplastic Breast Carcinoma ◽  
Triple Negative Subtype

BACKGROUND: Metaplastic breast carcinoma (MBC) is a rare type of breast cancer (0.20–1.00% of all cases). With a more aggressive clinical course, MBC frequently presents as a triple-negative subtype. OBJECTIVE: To describe a case series, analyzing patients survival in four MBC cases. METHODS: The cases were obtained from 532 medical records of breast cancer patients (0.7% of the total). RESULTS: All patients were female. Mean patient age was 49 years (range: 38–60 years). Mean tumor size was 8.9 cm (range: 3.0–15.5 cm). Mastectomy was performed in three cases. One patient had axillary nodal metastasis. All underwent chemotherapy and three received radiation therapy after surgery. CONCLUSIONS: With a mean follow-up of 36 months (range: 10–60 months), one case had a tumor recurrence (25%). Three patients (75%) died from metastatic disease and one (25%) is still alive and free of disease.

Nursing care to the women with breast cancer: literature review

2011 ◽  
Vol 5 (6) ◽  
pp. 1526
Author(s):  
Luciana Scatralhe Buetto ◽  
Rafaela De Souza Abrão ◽  
Rafaella Bianchi Besson ◽  
Helena Megumi Sonobe ◽  
Nariman De Felício Bortucan Lenza
Keyword(s):  
Breast Cancer ◽  
Literature Review ◽  
Nursing Care ◽  
Teaching And Learning ◽  
Therapeutic Process ◽  
Cáncer De Mama ◽  
Cancer Nursing ◽  
The Social ◽  
Las Mujeres ◽  
And Performance

ABSTRACTObjective: to analyze the national scientific production about the nursing care to the women with breast cancer, from 2005 to 2009. Methodology: literature review of 24 scientific articles, selected of digital search in the databases Lilacs and Scielo, with the terms “nursing care” and “breast cancer”. Results: the analysis resulted in two themes: “coping strategies used by the woman with breast cancer” and “performance of the nurse care to the women with breast cancer”. It is emphasized the need of education about the illness, as a strengthening strategy of these women in front of the diagnosis and to facilitate the therapeutic itinerary; and the importance of social, family, groups and multiprofessional support. Conclusion: this study enabled to verify the function of nurse in the therapeutic process of women with breast cancer, and the importance of teaching and learning process about the illness, favoring the treatment coping, the social and professional support. Descriptors: breast cancer; nursing care; oncology; neoplasm; women’s health.RESUMOObjetivo: analisar a produção científica nacional sobre os cuidados de enfermagem às mulheres com câncer de mama, no período de 2005 a 2009. Metodologia: revisão de literatura de 24 artigos científicos, selecionados da busca digital nas bases de dados Lilacs e Scielo, com os termos cuidados de enfermagem e câncer de mama. Resultados: a análise resultou em dois temas: “estratégias de enfrentamento utilizadas pela mulher com câncer de mama” e “atuação do enfermeiro no cuidado às mulheres com câncer de mama”. Destaca-se a necessidade de educação acerca da doença, como estratégia de fortalecimento destas diante do diagnóstico e para facilitar o itinerário terapêutico; e a importância do suporte social dos grupos de apoio e da família, e do suporte multiprofissional. Conclusão: O estudo possibilitou verificar o papel do enfermeiro no processo terapêutico das mulheres acometidas pelo câncer de mama, e a importância do processo ensino-aprendizagem na conscientização das mulheres sobre a doença, favorecendo o enfrentamento dos tratamentos, o suporte social e profissional. Descritores: câncer de mama; cuidados de enfermagem; oncologia; neoplasia; saúde da mulher. RESUMENObjetivo: analisar la producción cientifica nacional sobre los cuidados de enfermería a las mujeres con cáncer de mama, en el periodo de 2005 hasta 2009. Método: revisión de literatura de 24 artículos científicos, seleccionados en las basis digital de datos Lilacs y Scielo, con los términos cuidados de enfermería y cáncer de mama. Resultados: la análisis resultó en dos temas: estrategias de enfrentamiento utilizadas por la mujer con cáncer de mama y “la atuación del enfermero en el cuidado a las mujeres con cáncer de mama”. Destacáse la necesidad de enseñanza sobre la enfermedad, como estrategia de fortalecimiento de estas delante al diagnostico y para facilitar el itinerario terapéutico; la importancia del soporte social de los grupos de apoyo y de la familia, y del soporte multidisciplinar. Conclusión: el estudio posibilitó verificar el papel del enfermero en lo proceso terapéutico de las mujeres acometidas por cáncer de mama, y la importancia del proceso enseñanza-aprendizaje en la concienciación de las mujeres sobre la enfermedad, favorable al enfrentamiento de los tratamientos, al soporte social y profesional. Descriptores: cáncer de mama; cuidados de enfermería; oncología; neoplasia; salud de la mujer.

Single-institution experience with neoadjuvant chemotherapy for metaplastic breast cancer (MBC).

2012 ◽  
Vol 30 (27_suppl) ◽  
pp. 140-140
Author(s):  
Anna Kaminsky
Keyword(s):  
Breast Cancer ◽  
Breast Carcinoma ◽  
Neoadjuvant Chemotherapy ◽  
Triple Negative Breast Cancer ◽  
Tumor Volume ◽  
Triple Negative ◽  
Volume Reduction ◽  
Tumor Volume Reduction ◽  
Metaplastic Breast Carcinoma

140 Background: Metaplastic breast carcinoma (MBC) is a rare subtype that accounts for <1% of all breast carcinomas. MBC is frequently triple-negative and neoadjuvant chemotherapy (NAC) is often used in triple-negative breast cancer (TNBC). The objective of this analysis is to ascertain response rates of MBC to NAC as compared to non-metaplastic TNBC. Methods: We searched the Magee Women’s Cancer Center of UPMC IRB-approved neo-adjuvant treatment database which contains outcome data on 594 patients treated from 2004-2010. 116 patients with triple negative breast cancer (ER /PR negative or ER /PR weakly positive [H score of 10 or less] and HER2 negative or indeterminate [HER2 1+ or 2+ without amplification by FISH]), were identified. Nine of these TNBCs had metaplastic subtype and two groups were analyzed: metaplastic breast carcinoma (MBC) (N= 9) and non-metaplastic breast carcinoma (NMBC) (N = 107). Tumor volume reduction (TVR), pathologic complete response (pCR), recurrence and mortality were compared in both groups. Results: Average follow-up in MBC group was 43 months and no patients were lost to follow-up. Average tumor size on presentation in MBC group was 4.47 cm while in NMBC group it was 3.33 cm. pCR was noted in 0/9 MBC and 43/107 NMBC cases (p = 0.0253). 6/9 patients had mastectomy, 2/9 had breast conserving surgery (BCS) and 1/9 patients did not have a surgery yet. Average TVR was 28% in MBC cases compared to 74% in NMBCs when cases with pCR were included (p = 0.0001) and 56% when cases with pCR were excluded (p = 0.0202). Follow up on 9 MBC cases revealed 1 recurrence and subsequent death (11%). Follow-up on 64 NMBC patients who failed to achieve pCR revealed 22 recurrences (34%) and 18 of them subsequently died (28%). Follow-up on 43 NMBC cases that achieved pCR revealed 3 recurrences (7%) and 1 death (2%). Conclusions: MBC was characterized by larger size at baseline as compared to NMBC. There were no pCR’s seen in MBC, but some MBC did achieve response that allowed for breast conservation. Although the average tumor volume reduction was significantly less in MBC compared to NMBC, the NMBC that failed to achieve pCR fared much worse than MBC who did not achieve pCR. Therefore, the triple-negative paradox is likely not applicable to MBC.

scholarly journals Research on the Role of Combined Chemotherapy and Radiotherapy in Patients With N+ Non-Metastatic Metaplastic Breast Carcinoma: A Competing Risk Analysis Model Based on the SEER database, 2000 to 2015

2021 ◽  
Vol 10 ◽  
Author(s):  
Yifei Ma ◽  
Zejian Yang ◽  
Yihan Gao ◽  
Kunlong Li ◽  
Pei Qiu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Breast Carcinoma ◽  
Therapy Group ◽  
Model Analysis ◽  
Competing Risk ◽  
Mode Analysis ◽  
Combined Chemotherapy ◽  
Risk Of Death ◽  
Metaplastic Breast Carcinoma

PurposeDue to the rarity of metaplastic breast carcinoma (MpBC), no randomized trials have investigated the role of combined chemotherapy and radiotherapy (CCRP) in this condition. We aimed to explore and identify the effectiveness of CCRP in patients with regional lymph node metastasis (N+) non-metastatic MpBC.Materials and MethodsData were obtained from the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) Program database. We assessed the effects of CCRP on overall survival (OS), breast cancer-specific survival (BCSS), and breast cancer-specific death (BCSD) using Kaplan-Meier analysis, competing risk model analysis, and competing risk regression mode analysis.ResultsA total of 707 women and 361 death cases were included in the unmatched cohort, of which 76.45% (276/361) were BCSD, and 23.55% (85/361) were non-breast cancer-specific deaths (non-BCSD). Both the ChemT and CCRP groups had better OS (ChemT group: HR: 0.59, 95% CI: 0.45–0.78, P&lt;0.001; CCRP group: HR: 0.31, 95% CI: 0.23–0.41, P&lt;0.001) and BCSS (ChemT group: HR: 0.63, 95% CI: 0.45–0.87, P&lt;0.001; CCRP group: HR: 0.32, 95%CI: 0.22–0.46, P&lt;0.001) than the non-therapy group. Subjects in the CCRP group tended to have significantly lower cumulative BCSD (Gray’s test, P=0.001) and non-BCSD (Gray’s test, P&lt;0.001) than the non-therapy group or ChemT group. In competing risk regression model analysis, subjects in the CCRP group had a better prognosis in BCSD (HR: 0.710, 95% CI: 0.508–0.993, P=0.045) rather than the ChemT group (HR: 1.081, 95% CI: 0.761–1.535, P=0.660) than the non-therapy group.ConclusionOur study demonstrated that CCRP could significantly decrease the risk of death for both BCSD and non-BCSD and provided a valid therapeutic strategy for patients with N+ non-metastatic MpBC.

scholarly journals The Detailed Study of CD10: A Stromal Marker in Breast Carcinoma

2021 ◽  
pp. 62-70
Author(s):  
Huidrom Jyotsna Devi ◽  
P. Karkuzhali ◽  
P. K. Baskaran ◽  
S. Mary Lilly
Keyword(s):  
Public Health ◽  
Breast Cancer ◽  
Stem Cells ◽  
Stem Cell ◽  
Breast Carcinoma ◽  
Cell Surface ◽  
Acute Lymphoblastic Leukaemia ◽  
Lymphoblastic Leukaemia ◽  
The World ◽  
Apocrine Sweat Gland

Breast carcinoma is one of the most frequently occurring cancers among women with one million cases. Breast cancer is the primary cause of death in women around the world. It is one of the major concerns in public health due to its high occurrence and growing tendency.   This complex functional structure develops from a highly modified apocrine sweat gland in the female, but remains rudimentary in male. Breast develops embryological into two lines along milk lines extending from axilla to groin. CD-10 is a 90- to 110-kDa cell surface zinc dependent metalloproteinase which is known as “Common Acute Lymphoblastic Leukaemia Antigen” (CALLA). CD-10 acts  as a stem cell regulator in the breast and  prevents uncontrolled proliferation on stem cells The present study is designed to study the expression of CD-10, a breast carcinoma stromal marker and its correlation with ER, PR and HER2/neu status in breast carcinoma.

scholarly journals MARCADORES TUMORALES PRONÓSTICOS EN CÁNCER DE MAMA: BAX y Bcl-2

2022 ◽  
Vol 7 (1) ◽  
pp. 24
Author(s):  
Lizette Elena Leiva Suero ◽  
Yenddy Carrero Castillo ◽  
Graciela de las Mercedes Quishpe Jara ◽  
Sandra Villacís Valencia ◽  
Jesús Onorato Chicaiza Tayupanta ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Breast Carcinoma ◽  
Tumor Markers ◽  
Inhibitory Effect ◽  
Cáncer De Mama ◽  
Cell Models ◽  
Culture Cells ◽  
Carcinoma De Mama ◽  
Marcadores Tumorales ◽  
Mcf 7

Introducción: El carcinoma de mama representa el 16% de todos los cánceres femeninos, cada año en las Américas, más de 462,000 mujeres son diagnosticadas y casi 100,000 mueren por esta causa, por lo que la detección de nuevos marcadores pronósticos se hace imprescindible para el desarrollo de nuevas terapias oncológicas. Objetivo: Identificar los marcadores tumorales con fines pronósticos en cáncer de mama en células de cultivo de carcinoma de mama MCF7. Método: Se desarrolló un estudio explicativo longitudinal y prospectivo observacional para identificar marcadores tumorales con valor pronóstico en modelos celulares MCF7 de Cáncer de Mama, se utilizarán métodos estadísticos descriptivos e inferenciales. Resultados: Se identificó un predominio de Bcl-2 en las células de cultivo MCF7 de Carcinoma de Mama. Conclusión: La identificación de BAX y Bcl-2 en modelos celulares MCF 7 de Carcinoma de Mama permite evaluar nuevas opciones terapéuticas relacionadas con la inducción de la apoptosis. La predominancia Bcl-2 pudiera constituir un factor de mal pronóstico y menor supervivencia debido a su efecto inhibidor de la apoptosis, donde subyacen alteraciones mitocondriales, que inciden en la regulación del nivel de calcio intracelular, o por su efecto antioxidante.   Palabras clave: Neoplasias de la mama, Pronóstico, Apoptosis, Proteína de Susceptibilidad a Apoptosis Celular   ABSTRACT    Introduction: Breast carcinoma represents 16% of all female cancers, each year in the Americas, more than 462,000 women are diagnosed and almost 100,000 die from this cause, so the detection of new prognostic markers is essential for the development of new oncological therapies. Objective: To identify tumor markers for prognostic purposes in breast cancer in MCF7 breast carcinoma culture cells. Method: A longitudinal and prospective observational explanatory study was developed to identify tumor markers with prognostic value in MCF7 cell models of Breast Cancer, descriptive and inferential statistical methods will be used. Results: A predominance of Bcl-2 was identified in the MCF7 culture cells of Breast Carcinoma. Conclusion: The identification of BAX and Bcl-2 in MCF 7 cell models of Breast Carcinoma allows to evaluate new therapeutic options related to the induction of apoptosis. The Predominance bcl-2 could constitute a factor of poor prognosis and lower survival due to its inhibitory effect of apoptosis, where mitochondrial alterations underlie, which affect the regulation of the level of intracellular calcium, or for its antioxidant effect. Keywords: Breast Neoplasms, Prognosis, Apoptosis, Cellular Apoptosis Susceptibility Protein

Single institution experience with neoadjuvant chemotherapy for metaplastic breast cancer (MBC).

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 1038-1038 ◽  
Author(s):  
Anna Kaminsky ◽  
Rohit Bhargava ◽  
Kandace P McGuire ◽  
Shannon Puhalla
Keyword(s):  
Breast Cancer ◽  
Breast Carcinoma ◽  
Neoadjuvant Chemotherapy ◽  
Triple Negative Breast Cancer ◽  
Tumor Volume ◽  
Triple Negative ◽  
Volume Reduction ◽  
Tumor Volume Reduction ◽  
Metaplastic Breast Carcinoma

1038 Background: Metaplastic breast carcinoma (MBC) is a rare subtype that accounts for <1% of all breast carcinomas. MBC is frequently triple negative and neoadjuvant chemotherapy (NAC) is often used in triple negative breast cancer (TNBC). The objective of this analysis is to ascertain response rates of MBC to NAC as compared to non-metaplastic TNBC. Methods: We searched the Magee Women’s Cancer Center of UPMC IRB-approved neo-adjuvant treatment database which contains outcome data on 594 patients treated from 2004-2010. 116 patients with triple negative breast cancer (ER /PR negative or ER /PR weakly positive (H score of 10 or less) and HER2 negative or indeterminate (HER2 1+ or 2+ without amplification by FISH)), were identified. Nine of these TNBCs had metaplastic subtype and 2 groups were analyzed: metaplastic breast carcinoma (MBC) (N= 9) and non-metaplastic breast carcinoma (NMBC) (N = 107). Tumor volume reduction (TVR), pathologic complete response (pCR), recurrence and mortality were compared in both groups. Results: Mean follow up in MBC group was 43 months and no patients were lost to follow up. Mean tumor size on presentation in MBC group was 4.47 cm while in NMBC group it was 3.33 cm. pCR was noted in 0/9 MBC and 43/107 NMBC cases (p = 0.0253). 6/9 patients had mastectomy, 2/9 had breast conserving surgery (BCS) and 1/9 patients did not have a surgery yet. Average TVR was 28% in MBC cases compared to 74% in NMBCs when cases with pCR were included (p = 0.0001) and 56% when cases with pCR were excluded (p = 0.0202). Follow up on 9 MBC cases revealed 1 recurrence and subsequent death (11%). Follow up on 64 NMBC patients who failed to achieve pCR revealed 22 recurrences (34%) and 18 of them subsequently died (28%).Follow up on 43 NMBC cases that achieved pCR revealed 3 recurrences (7%) and 1 death (2%). Conclusions: MBC was characterized by larger size at baseline as compared to NMBC. There were no pCR’s seen in MBC, but some MBC did achieve response that allowed for breast conservation. Although the average tumor volume reduction was significantly less in MBC compared to NMBC, the NMBC that failed to achieve pCR fared much worse than MBC who did not achieve pCR. Therefore, the triple negative paradox is likely not applicable to MBC.

Sign in / Sign up

Export Citation Format

Share Document